Regulus Therapeutics Priced, Nasdaq: RGLS
Early stage biotech developing microRNAs treatments for multiple serious diseases.
Industry: Health Care
First Day Return: +5.0%
Industry: Health Care
RGLS
Early stage biotech developing microRNAs treatments for multiple serious diseases.
| IPO Data | |
|---|---|
| IPO File Date | 08/17/2012 |
| Offer Price | $4.00 |
| Price Range $4.00 - $4.00 | |
| Offer Shares (mm) | 11.3 |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 10/04/2012 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $45 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | San Diego, CA, United States |
| Founded | 2007 |
| Employees at IPO | 56 |
| Website www.regulusrx.com | |
IPO News for Regulus Therapeutics
Regulus Therapeutics (RGLS) Performance
